Recent news on Chlorambucil

New drug improves long term survival for mantle cell lymphoma  -  May 22, 2007
TopCancerNews.com,The usual treatment is MCP(mitoxantrone, chlorambucil, and prednisolone), a type of chemotherapy. The Journal of Clinical Oncology found that by adding

Innovative Cancer Drug MabThera Again Shown To Improve Survival ...  -  May 21, 2007
PharmaLive.com (press release),Hematological Malignancies _ Rituximab Added to First-Line Mitoxantrone, Chlorambucil and Prednisolone Chemotherapy Followed by Interferon Maintenance

Addition of Rituxan® to MCP Improves Survival in Follicular and ...  -  May 2, 2007
Cancer Consultants (press release),Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients

Genzyme seeks expanded FDA approval for Campath  -  Apr 5, 2007
Bizjournals.com,Chlorambucil is currently the standard first-line treatment. Campath was developed in San Antonio by ILEX Oncology Inc., which merged with Genzyme in 2004.

Expanded Label Filed for Campath®  -  Apr 9, 2007
Cancer Consultants (press release),The sBLA submission is based on results from a phase III clinical trial directly comparing Campath to chlorambucil (Leukeran®) as initial therapy for the

Genzyme seeks Campath expanded use  -  Apr 4, 2007
United Press InternationalGenzyme said a phase 3 study showed Campath worked better as first-line treatment, compared to to the cancer drug chlorambucil.

Genzyme Files for Expanded Label for Campath® as First-Line Treatment  -  Apr 7, 2007
WebWire (press release),...safety profile as compared to chlorambucil,� stated Mark Enyedy, senior vice-president and general manager of Genzyme’s oncology business unit.

MCP Chemotherapy Regimen May Reduce Amount of Stem Cells Collected ...  -  Feb 1, 2007
Cancer Consultants (press release),According to results recently published in Annals of Oncology, the chemotherapy regimen consisting of melphalan, chlorambucil, and prednisone (MCP) appears

Improving Outcomes in Lymphoma  -  Feb 5, 2007
Medscape (subscription)Addition of rituximab to first-line MCP (mitoxantrone, chlorambucil, prednisolone) chemotherapy prolongs survival in advanced follicular lymphoma - 4 year

Genzyme Reports Financial Results for Fourth Quarter of 2006 and ...  -  Feb 14, 2007
WebWire (press release),...meeting demonstrated that Campath significantly improved progression-free survival in comparison to chlorambucil in previously untreated B-CLL patients,

Genzyme Reports Strong Fourth-Quarter Revenue Growth to Conclude ...  -  18 Jan 2007
Oxfordshire Bioscience Network (press release),...of Hematology meeting demonstrated that Campath significantly improved progression-free survival in comparison to chlorambucil in previously untreated

Data From Phase III Comparative Study Show Campath® Superior to ...  -  Dec 13, 2006
Oxfordshire Bioscience Network (press release),The study met its primary endpoint by demonstrating superior progression free survival in patients treated with Campath versus chlorambucil, with Campath

Campath shown to be more effective in treating leukemia than ...  -  Dec 12, 2006
Phoenix Business Journal,It also found that Campath patients experienced a nearly 30 percent greater overall response rate than chlorambucil and a 12-fold increase in complete

0.0001), representing a 12-fold higher CRR with alemtuzumab ...  -  Dec 11, 2006
ANP Pers Support,...patients reaching a complete response with chlorambucil. Studies suggest that aiming to. a low white blood cell count).

Schering's phase III trial on MabCampath reveals superiority to ...  -  Dec 11, 2006
Forbes,FRANKFURT (AFX) - Schering AG said results of a phase III trial show that its MabCampath treatment is superior to chlorambucil for previously-untreated

Final Data from Phase III Study Show Single-Agent Alemtuzumab ...  -  Dec 12, 2006
PipelineReview.com (press release),..."This study demonstrates that alemtuzumab is superior as a first-line therapy compared to chlorambucil," stated lead investigator Peter Hillmen, MB, Ch.B,

Final Data from Phase III Study Show Single-Agent Alemtuzumab ...  -  Dec 11, 2006
netPR.pl (komunikaty prasowe),1) These data showed alemtuzumab (MabCampath(R)) was superior to chlorambucil as a first-line therapy with respect to progression free survival (PFS) in

Analysis: Transplant drug fights leukemia  -  Dec 11, 2006
Science Daily (press release)That was significantly greater that patients who responded to an alternative medication, chlorambucil, Hillmen said. But the bigger story, he added,

Alemtuzumab Appears Promising as First-Line B-cell Chronic ...  -  Dec 11, 2006
DG NewsThey randomized 149 subjects to receive Campath 30 mg IV 3 times per week for up to 12 weeks and 148 to chlorambucil 40 mg/m 2 by mouth every 28 days for up

Invitrogen Features New Scientific Online Resources and Celgene ...  -  Dec 12, 2006
Financial News USA (press release),The study compared Campath with chlorambucil in previously untreated patients with B-cell chronic lymphocytic leukemia. The study met its primary endpoint

Schering's Campath reports promising first-line Ph III data  -  Dec 12, 2006
Pharma Times (subscription),...showed that Campath (alemtuzumab) resulted in superior progression free survival compared to chlorambucil in previously untreated patients with B-cell

Campath shows superiority to treat B-CLL  -  Dec 11, 2006
United Press International11 (UPI) -- US firm Genzyme's drug Campath beats chlorambucil as a first-line therapy for B-cell chronic lymphocytic leukemia, the firms said Monday.

UPDATE 1-Bayer's Schering says Campath trial positive  -  Dec 11, 2006
ReutersData from the comparative study showed Campath superior to chlorambucil as a first-line therapy in chronic lymphocytic leukaemia (B-CLL), Schering said in a

Trial shows new leukaemia drug is 'more effective'  -  Dec 13, 2006
Leeds Today,...that alemtuzumab, known as MabCampath, had a positive effect in 83 per cent of patients in the worldwide study compared to another drug, chlorambucil."

(PRN) - Central European Telecommunications Provider Selects Sonus ...  -  Dec 12, 2006
Bolsamania.com,...(PRN) - Final Data from Phase III Study Show Single-Agent Alemtuzumab (MabCampath(R)) Superior to Chlorambucil for Patients with Previously Untreated B-CLL

FOCUS Bayer's HealthCare division to suffer from pipeline delays ...  -  Dec 11, 2006
Forbes,Schering today reported results of a phase III trial revealing that its MabCampath treatment is superior to chlorambucil for previously-untreated patients

(PRN) - Stream Restoration at Cielo Falls Will Mean Clear Water ...  -  Dec 11, 2006
Bolsamania.com,...(PRN) - Final Data from Phase III Study Show Single-Agent Alemtuzumab (Campath(R), MabCampath(R)) Superior to Chlorambucil for Patients with Previously

(PRN) - Revolutionary, All-in-One Spa Bed Combines Tanning With ...  -  Dec 11, 2006
Bolsamania.com,...(PRN) - Data From Phase III Comparative Study Show Campath(R) Superior to Chlorambucil as a First-line Therapy in B-CLL ... [+]

Genzyme's third-quarter earnings tumble, charges offset sales ...  Oct 12, 2006
The company is in the process of compiling final results from the Phase 3 trial comparing Campath with chlorambucil in previously untreated patients with ... -San Antonio Business Journal, Genzyme Reports Strong Third-Quarter Financial Results  Oct 12, 2006
Final results from the phase 3 trial comparing Campath with chlorambucil in previously untreated patients with progressive B-cell chronic lymphocytic leukemia ... -Yahoo! News (press release) Campath shown to be more effective in treating leukemia than ...  -  12 Dec 2006
Phoenix Business Journal,It also found that Campath patients experienced a nearly 30 percent greater overall response rate than chlorambucil and a 12-fold increase in complete

Invitrogen Features New Scientific Online Resources and Celgene ...  -  12 Dec 2006
Financial News USA (press release),The study compared Campath with chlorambucil in previously untreated patients with B-cell chronic lymphocytic leukemia. The study met its primary endpoint

(PRN) - Central European Telecommunications Provider Selects Sonus ...  -  12 Dec 2006
Bolsamania.com,...(PRN) - Final Data from Phase III Study Show Single-Agent Alemtuzumab (MabCampath(R)) Superior to Chlorambucil for Patients with Previously Untreated B-CLL

FOCUS Bayer's HealthCare division to suffer from pipeline delays ...  -  Dec 11, 2006
Forbes,Schering today reported results of a phase III trial revealing that its MabCampath treatment is superior to chlorambucil for previously-untreated patients

(PRN) - Stream Restoration at Cielo Falls Will Mean Clear Water ...  -  Dec 11, 2006
Bolsamania.com,...(PRN) - Final Data from Phase III Study Show Single-Agent Alemtuzumab (Campath(R), MabCampath(R)) Superior to Chlorambucil for Patients with Previously

(PRN) - Revolutionary, All-in-One Spa Bed Combines Tanning With ...  -  Dec 11, 2006
Bolsamania.com,...(PRN) - Data From Phase III Comparative Study Show Campath(R) Superior to Chlorambucil as a First-line Therapy in B-CLL ... [+]

Patients 80 Years or Older With NHL Benefit from Chemotherapy  Aug 15, 2006
...therapy. Among the 79 patients treated with chemotherapy 15 received single agent chlorambucil and 2 received oral etoposide. Combination ... -Cancer Consultants

BTG plc Releases 2006 AGM Statement  Jul 26, 2006
...reported encouraging results from an interim analysis of a phase III trial comparing Campath® with chlorambucil, a commonly prescribed alkylating agent, in ... -PharmaLive.com

Delivers Solid Earnings Growth Based on Strong Top-Line ...  Jul 18, 2006
A phase 3 trial comparing Campath with chlorambucil in previously untreated patients with progressive B-cell chronic lymphocytic leukemia (B-CLL) may ... -Oxfordshire Bioscience Network

Campath shown to be more effective against leukemia than standard ...  Jun 30, 2006
...conference in Atlanta that patients with progressive B-cell chronic lymphocyctic leukemia responded more favorably to Campath (alemtuzumab) than chlorambucil. ... -San Antonio Business Journal

Reduced Intensity Allogeneic Stem Cell Transplantation in Fludara ...  Jun 22, 2006
...an increasing number of treatment options available for patients CLL including: alkylating agents (cyclophosphamide and chlorambucil), Fludara® (fludarabine ... -Cancer Consultants

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional